Beckman Coulter Stock Gain Aided By Merger Activity In Diagnostics – Index
This article was originally published in The Gray Sheet
Clinical diagnostics firm Beckman Coulter's stock is benefiting from recent merger activity among its rivals in the field and speculation that it too could become an acquisition target; shares advanced 14% in the third quarter to close at $73.76
You may also be interested in...
Siemens' medical unit solidified its status July 25 as the only company offering a comprehensive suite of both imaging and in vitro diagnostic products with its $7 billion acquisition of Dade Behring
ReAble Therapeutics agreed July 16 to buy DJO for about $1.6 billion in a deal that will give the privately held firm a substantial stake in the bracing and soft goods orthopedic market and complement its current strength in electrotherapy pain management
Future cuts to home oxygen equipment payments may be even greater than some manufacturers anticipate, according to a 1report released July 9 by Avalere Health